Drug Interactions Corner

Back to articles

Examining drug-drug interactions in HIV treatment

KEY POINT

Two recently published studies shed light on clinically significant drug–drug interactions (CSDDIs) in patients with HIV. Researchers examined CSDDIs among patients treated with antiretroviral regimens based on nonnucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors, and raltegravir (Isentress—Merck). In the other trial, researchers compared CSDDI risks in young and old patients with HIV on antiretroviral therapy.

REVISIONS

Patel N et al. Predictors of clinically significant drug–drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor–, protease inhibitor–, and raltegravir-based antiretroviral regimens. Ann Pharmacother. 2011;45(3):317–24.

Nguyen N et al. Clinically significant drug interactions in younger and older human immunodeficiency virus–positive patients receiving antiretroviral therapy. Pharmacotherapy. 2010;31(5):480–9.